Cytogenix (fka CYGX)

[Paulness]

37 hours 20 minutes until Geneva conference .ADDRESSING A PANDEMIC THROUGH RAPID SCALE-UP

http://www.terrapinn.com/2007/biopharm/confprog.stm

11.20 Producing DNA vaccines using a novel non-fermentation technology

Manufacturing DNA vaccines using a non-fermentation technology and potential for rapid scale-up
A review of successes with DNA vaccines and their potential applications

Yin Chen, Vice President, Research and Development,
CytoGenix


11.40 Panel session: the future of DNA and non egg cell based vaccines

What is the potential for scale-up compared to egg cell vaccines?
How do DNA vaccines compare to non-egg cell vaccines?
What key successes have been achieved with DNA vaccines?

Moderator:
Hans Huber, Technology Agent - Biopharmacetuical Production,
Boehringer Ingelheim Austria
Confirmed:
Yin Chen, Vice President, Research and Development,
CytoGenix
Confirmed:
Simon Thompson, Project Manager,
Genvax Ltd / MMI Group
Confirmed:
Norbert Klein, Site Head Technical Operations,
Novartis Vaccines and Diagnostics